Sign the petition to share your support for stage IV breast cancer patients.Read more about how we plan to take action
How we plan to take action.
The Canadian Breast Cancer Network will meet with federal regulators to discuss how a well-designed national pharmacare program can help Canadians living with stage IV breast cancer live better and longer lives. In order to meet the needs of these patients, a national pharmacare program must:
- Cover all EXISTING therapies with demonstrated efficacy: Patients should have access to all Health Canada approved breast cancer therapies that have demonstrated efficacy and safety. Effective medications shouldn’t be removed from the formulary just because a new medicine is added to the formulary, and changes the line-sequencing of current treatments. Evidence-building programs and the collection of real-world evidence should be analyzed to inform whether older medications are effective in later line settings as new medications become available.
- Cover all NEW therapies with demonstrated efficacy: Patients should have access to all new breast cancer therapies that are approved by Health Canada that have demonstrated efficacy and safety.
- Provide timely access to new therapies: The health technology assessment process and negotiations with manufacturers needs to be streamlined to reduce duplication and expedite access to new innovative treatments for stage IV metastatic breast cancer.